A patient with type 2 diabetes is started on empagliflozin. Beyond glucose lowering, which mechanism underlies its proven cardiovascular mortality benefit in the EMPA-REG OUTCOME trial?
- A GLP-1 receptor agonism causing direct cardioprotective signaling
- B Natriuresis and osmotic diuresis reducing preload and afterload, with possible direct cardiac energetic effects via ketone body utilization by the myocardium ✓
- C Inhibition of the renin-angiotensin-aldosterone system reducing myocardial fibrosis
- D Reduction of LDL-cholesterol by activating hepatic LDL receptors
Explanation
SGLT2 inhibitors like empagliflozin promote glycosuria, natriuresis, and osmotic diuresis, reducing plasma volume and cardiac preload. The cardiovascular benefits appear to extend beyond simple volume reduction and include reduction in cardiac oxygen demand, anti-inflammatory effects, and potentially preferential utilization of ketone bodies (a more energy-efficient fuel) by the failing myocardium. These hemodynamic and metabolic effects explain the rapid divergence of cardiovascular event curves in EMPA-REG OUTCOME, suggesting a mechanism beyond atherosclerosis regression.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.